AIDS 2024 Pharmacist Perspectives

CE

Integrating New Data From AIDS 2024: Pharmacist Perspectives

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: September 04, 2024

Expiration: September 03, 2025

Jennifer Cocohoba
Jennifer Cocohoba, PharmD, AAHIVP
David Koren
David Koren, PharmD, MPH, AAHIVP, FIDSA

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the PURPOSE 1 study in cisgender women, compared with background HIV incidence, HIV incidence was:

2.

Your colleague asks you whether there are data to support efficacy and acceptability to use LA CAB + RPV in adolescents with HIV. You tell them that, at Wk 48 of the IMPAACT 2017 study, there were:

3.

Your colleague asks about evidence behind switching a virologically suppressed person to an INSTI-based regimen. You advise them that, in the PASO-DOBLE study, switching to DTG/3TC compared with BIC/FTC/TAF resulted in:

4.

I am familiar with data from the AIDS 2024 conference, and I plan to translate these data into current or future management strategies.